Watch on YouTube

It was my privilege to interview Mo Khan, CEO of hVIVO for Vox Markets, ahead of today's half-year trading update.

Mo has outstanding credentials, with 25 years experience in clinical research coupled with success in working with private equity in M&A activity. hVIVO has enjoyed considerable success in the development of cures in respiratory, virology and immunology development. 

It is hVIVO's intention to add further development cures to its portfolio unconnected with respiratory issues. These are exciting times for this innovative operation and it should not be long before the fruits of its labour manifest themselves